RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES, Feb. 24, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or “the Company”) (NASDAQ: RARE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 3, 2023 and December 26, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before April 6, 2026.

GlobeNewsWire • 9 hours ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RARE

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at  [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

GlobeNewsWire • 2 hours ago

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Ultragenyx Pharmaceutical Inc.(RARE) Shareholders

NEW YORK, Feb. 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). Shareholders who purchased shares of RARE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

PRNewsWire • 10 hours ago

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE

New York, New York--(Newsfile Corp. - February 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purchased Ultragenyx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Newsfile Corp • 4 hours ago

RARE UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - February 24, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ultragenyx Pharmaceutical Inc ("Ultragenyx" or the "Company") (NASDAQ: RARE) and reminds investors of the April 6, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Newsfile Corp • 2 hours ago

Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud: Contact Berger Montague To Discuss Your Rights

Philadelphia, Pennsylvania--(Newsfile Corp. - February 24, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) ("Ultragenyx" or the "Company") on behalf of investors who purchased Ultragenyx common stock during the period from August 3, 2023 through December 26, 2025 (the "Class Period"). Investor Deadline: Investors who purchased Ultragenyx securities during the Class Period may, no later than April 6, 2026, seek to be appointed as a lead plaintiff representative of the class.

Newsfile Corp • 10 hours ago

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES, Feb. 23, 2026 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") (NASDAQ: RARE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before April 6, 2026.

PRNewsWire • Feb 23, 2026

Ultragenyx Pharmaceutical Inc. Securities Class Action Filed; Lead Plaintiff Deadline April 6, 2026 – RGRD Law

SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023 and December 26, 2025, inclusive (the “Class Period”), have until Monday, April 6, 2026 to seek appointment as lead plaintiff of the Ultragenyx class action lawsuit. Captioned Bailey v.

GlobeNewsWire • Feb 23, 2026

ROSEN, A RANKED AND LEADING FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the “Class Period”), of the important April 6, 2026 lead plaintiff deadline.

GlobeNewsWire • Feb 23, 2026

Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

PDUFA action date set for August 23, 2026 If approved, DTX401 will be the first treatment to address the underlying cause of GDSIa NOVATO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted for review the Biologics License Application (BLA) seeking approval of DTX401 AAV gene therapy (pariglasgene brecaparvovec) for the treatment of Glycogen Storage Disease Type Ia (GSDIa).

GlobeNewsWire • Feb 23, 2026